Current studies into retatruptide peptide demonstrate notable outlook for treating weight and type diabetes mellitus. The molecule, a dual activator of GLP-1 and GIP receptor, seems to provide greater weight loss and glycemic control versus existing therapies. Further patient studies are necessary to thoroughly determine its safety record and long-